Our Take
Healthcare's consent frameworks are structurally slower than other regulated industries, and two conferences in 2026 signal the field is finally naming the problem—but has no solution yet.
Why it matters
AI deployment in healthcare depends on patient consent and data-use agreements, but healthcare's consent models remain rigid compared to financial services or e-commerce. HIMSS26 APAC and the AI in Healthcare Forum are explicitly positioning the move from pilot ambition to evidence-based implementation, suggesting the industry recognizes this friction is now a bottleneck.
Do this week
Healthcare IT leaders: audit your current consent workflows against your finance or retail peer institutions' data-use agreements before attending HIMSS26 APAC in August so you can identify which specific consent barriers block your AI roadmap.
Healthcare consent frameworks lag industry peers
Healthcare systems operate under consent and data-governance rules that are materially stricter than those in finance, retail, and technology. While other regulated industries have developed flexible consent mechanisms that allow broader secondary use of customer or member data, healthcare consent models remain binary and narrow: explicit consent is required for most uses beyond the original treatment purpose.
Two major conferences scheduled for 2026 are now directly addressing this gap. HIMSS26 APAC, running August 23-25 in Singapore, will convene healthcare leaders, government voices, clinicians, and technologists to explore how health systems can move from AI ambition to evidence-based action. The AI in Healthcare Forum, scheduled for June 25-26 in Boston, brings together clinicians, executives, technologists, researchers, and innovators for two days focused on real-world AI application in health and care.
Neither conference has published specific consent frameworks or proposed changes, but the explicit framing of both events around the transition from ambition to evidence signals that industry organizers view consent flexibility as a material blocker to deployment at scale.
Consent lag directly blocks AI deployment
Healthcare AI projects require patient data for training, validation, and continuous improvement. Unlike finance or retail, where consent can be bundled into terms of service or membership agreements, healthcare requires explicit opt-in for secondary research or AI training use in most jurisdictions.
This creates a practical friction: clinicians and health IT executives can build AI workflows and run successful pilots, but operationalizing those workflows at the health system or network level often requires re-consenting existing patient populations or restricting AI to new patients only. Other industries solved this decades ago through flexible consent language and periodic re-consent campaigns. Healthcare has not.
The timing of both conferences in mid-2026 suggests the field is moving past acknowledgment of the problem toward active solution-building. No vendor or regulatory body has yet proposed a standard consent template that bridges healthcare's fiduciary requirements and the data flexibility that AI models need.
What to prepare for these events
Practitioners attending either conference should come with a specific inventory: which AI use cases in your roadmap are blocked by current consent language, and which jurisdiction's regulatory framework (HIPAA, GDPR, PIPEDA, or other) creates the tightest constraint for your organization.
Bring a copy of your current patient consent form and your data-use agreement with your EHR vendor. Compare the specific language that permits or restricts secondary uses. This comparison will clarify whether your bottleneck is legal interpretation, operational process, or genuinely missing consent language.
Expect the conferences to surface proposed solutions (regulatory safe harbors, template consent language, third-party consent platforms) rather than deliver a consensus standard. The field is still in discovery mode. The value will be in identifying which solutions your organization can pilot with your legal and compliance teams before the next funding cycle.